U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H8O4
Molecular Weight 180.1578
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CAFFEIC ACID

SMILES

c1cc(c(cc1/C(/[H])=C(\[H])/C(=O)O)O)O

InChI

InChIKey=QAIPRVGONGVQAS-DUXPYHPUSA-N
InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+

HIDE SMILES / InChI
Molecular Formula C9H8O4
Molecular Weight 180.1578
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Caffeic acid is an organic compound that is classified as a hydroxycinnamic acid. Caffeic acid is naturally found in many agricultural products, such as fruit, vegetables, wine, olive oil, and coffee, and therefore, significantly present in human diet. Caffeic acid has been reported to have a wide variety of biological activities, including antioxidants, antithrombosis, antihypertensive, antifibrosis, antiviral and anti-tumor properties. Caffeic acid can be effectively employed as a natural antioxidant in various food products such as oils. Caffeic acid exhibits potent anticancer effect in HT-1080 cell line and that it may be used as an anticancer agent. Caffeic acid showed neuroprotective action against oxidative and DNA damage produced in the kindling epilepsy model, although they did not produce antiepileptogenic effect in vivo. Caffeic acid was effective in patients with primary immune thrombocytopenia. Detected in clinical trial caffeic acid-related adverse events were: mild nausea and elevation of liver enzymes.

CNS Activity

Originator

Wolfrom, M.L. et al.
1
Sources: DOI: 10.1021/jf60107a016

Approval Year

2020
833
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1343
Inhibitor
7728
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Phase III
643
Unknown

Approved Use

Unknown
Primary
Phase IV
63
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition of HIV replication by Hyssop officinalis extracts.
1990 Dec
Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication.
1991
Inhibition of HIV-1 proteinase by non-peptide carboxylates.
1991 Apr 15
In vitro and in vivo reversible and irreversible inhibition of rat glutathione S-transferase isoenzymes by caffeic acid and its 2-S-glutathionyl conjugate.
1993 Jul
Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.
1996 Jun 25
Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
1996 Oct
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.
1998 Jan
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
1999 Feb 11
In vitro activity of polyhydroxycarboxylates against herpesviruses and HIV.
2001 Nov
Anti-HIV activities of natural antioxidant caffeic acid derivatives: toward an antiviral supplementation diet.
2005
Urinary flavonoids and phenolic acids as biomarkers of intake for polyphenol-rich foods.
2006 Jul
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006 Nov
Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice.
2007 Apr
Cigarette smoke toxicants as substrates and inhibitors for human cytosolic SULTs.
2007 May 15
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines.
2010 Oct 6
Protective effects of caffeic acid on lactate dehydrogenase isoenzymes, electrocardiogram, adenosine triphosphatases, and hematology on isoproterenol-induced myocardial infarcted rats.
2011 Mar-Apr
Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
2012 Aug
Caffeic acid attenuates 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced NF-κB and COX-2 expression in mouse skin: abrogation of oxidative stress, inflammatory responses and proinflammatory cytokine production.
2012 Feb
Oral administration of caffeic acid ameliorates the effect of cisplatin on brush border membrane enzymes and antioxidant system in rat intestine.
2013 Jan
Patents

Patents

04521438
1
07074620
1
07273920
1
JP2001240527A
1
JP2002080360A
2
JP2002155017A
1
JP2002541233A
371
JP2005089676A
2
JP2007297296A
1
JP2008106013A
5
JP2008278780A
2
JP2009029657A
1
JP2009100760A
1
JP2009526755A
410
JP2010120908A
1
JP2011057687A
1
JPH01132344A
1
JPH02235852A
1
JPH05286835A
4
JPH05311472A
1
JPH0616537A
1
JPH08208419A
1
JPH08259453A
1
JPH08337516A
2
JPH09151130A
1
JPH10117680A
4
JPH10179079A
1
JPH10183164A
1
JPH10262547A
2
JPH10273404A
1
JPS59155314A
2
JPS63168464A
1

Sample Use Guides

In Vivo Use Guide
300mg three times a day
Route of Administration: Oral
In Vitro Use Guide
Caffeic acid treatment significantly increased ROS level in HT-1080 cells. Among all the doses tested, 50 ug/ml of Caffeic acid showed the maximum generation of ROS (95%) in HT-1080 cells.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:27:37 UTC 2021
Edited
by admin
on Fri Jun 25 21:27:37 UTC 2021
Record UNII
U2S3A33KVM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAFFEIC ACID
DSC   HSDB   INCI   MI   USP-RS  
INCI  
Official Name English
3,4-DIHYDROXYBENZENEACRYLIC ACID
Systematic Name English
CAFFEIC ACID [DSC]
Common Name English
2-PROPENOIC ACID, 3-(3,4-DIHYDROXYPHENYL)-, (2E)-
Code English
4-(2-CARBOXYETHENYL)-1,2-DIHYDROXYBENZENE
Systematic Name English
CAFFEIC ACID [INCI]
Common Name English
CAFFEIC ACID (CONSTITUENT OF BLACK COHOSH) [DSC]
Common Name English
3-(3,4-DIHYDROXYPHENYL)-2-PROPENOIC ACID
Systematic Name English
CAFFEIC ACID [IARC]
Common Name English
CINNAMIC ACID, 3,4-DIHYDROXY-
Common Name English
CAFFEIC ACID [WHO-DD]
Common Name English
CAFFEIC ACID [HSDB]
Common Name English
NSC-57197
Code English
NSC-623438
Code English
CAFFEIC ACID [MI]
Common Name English
TRANS-3,4-DIHYDROXYCINNAMIC ACID
Common Name English
TRANS-CAFFEIC ACID
Common Name English
2-PROPENOIC ACID, 3-(3,4-DIHYDROXYPHENYL)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C68539
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
DSLD 1678 (Number of products:14)
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C68540
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-361-2
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
MESH
C040048
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
PUBCHEM
689043
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
WIKIPEDIA
CAFFEIC ACID
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
CAS
331-39-5
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
RXCUI
1311397
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M2908
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY Merck Index
HSDB
331-39-5
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
CAS
501-16-6
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
EPA CompTox
331-39-5
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
FDA UNII
U2S3A33KVM
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
DRUG BANK
DB01880
Created by admin on Fri Jun 25 21:27:37 UTC 2021 , Edited by admin on Fri Jun 25 21:27:37 UTC 2021
PRIMARY
Related Record Type Details
CENTAURIUM ERYTHRAEA WHOLE
PARENT -> CONSTITUENT ALWAYS PRESENT
GALIUM APARINE WHOLE
PARENT -> CONSTITUENT ALWAYS PRESENT
VACCINIUM MYRTILLUS LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
IPOMOEA AQUATICA LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
19.2% reaction on PG synthase w/10.0 mM conc. of compound
COMFREY ROOT
PARENT -> CONSTITUENT ALWAYS PRESENT
BLACK COHOSH
PARENT -> CONSTITUENT ALWAYS PRESENT
CYNARA SCOLYMUS LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
COMFREY LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
MENYANTHES TRIFOLIATA LEAF
PARENT -> CONSTITUENT ALWAYS PRESENT
ARCTIUM LAPPA ROOT
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
Structure of 3-(3,4-DIHYDROXYPHENYL) PROPIONIC ACID
METABOLITE -> PARENT
Related Record Type Details
Structure of CAFFEIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966